Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial

OBJECTIVE: BEYOND trial evaluated the feasibility of either basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1RA) or basal insulin plus sodium–glucose cotransporter 2 inhibitor (SGLT2i) to replace a full basal-bolus insulin (BBI) regimen in participants with type 2 diabetes and inade...

Descripción completa

Detalles Bibliográficos
Autores principales: Giugliano, Dario, Longo, Miriam, Caruso, Paola, Di Fraia, Rosa, Scappaticcio, Lorenzo, Gicchino, Maurizio, Petrizzo, Michela, Bellastella, Giuseppe, Maiorino, Maria Ida, Esposito, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247516/
https://www.ncbi.nlm.nih.gov/pubmed/33883195
http://dx.doi.org/10.2337/dc20-2623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247516/
https://www.ncbi.nlm.nih.gov/pubmed/33883195
http://dx.doi.org/10.2337/dc20-2623

Ejemplares similares